Abstract
Parmenides said that what cannot be thought, cannot be, therefore, what can be, can be thought. So it was that ancient Greek philosophers had thought of the atoms, and particularly, the radioactive atoms we use in Nuclear Medicine. Indeed, Democritos in the sixth century bc formulated the idea of the atoms as the indestructible smaller elements of the universe that combine among themselves to form the visible world; he thought of atoms on a philosophical basis as the explanation of the changes in the environment, which occur without the perishment of matter. Rearrangements of “atoms” could explain the changes around us and inside us. Two centuries later, Epicuros, as if anticipating the discovery of the radioactive atoms, introduced the idea of the “unstable” atom, which, after a period of instability, takes its final stable form. More than 2,000 years later, when science overtook these frontiers, John Dalton knew Democritos’ Atomic Theory of Matter and used it to explain chemical experiments. If the atom (=not possible to cut) can be cut and split into parts, it is not Democritos’ fault. Today we understand that by “atoms” Democritos actually meant the “quarks” or the “strings,” or perhaps some other, yet to be discovered, elemental particles. As for Henri Beckerel and Marie Curie, who were among the first to deal with radioactivity and the “unstable” or “radioactive atoms,” it is not known if they knew that the theoretical father of Nuclear Science was Epicuros. In Nuclear Medicine, we use the “radioactive atoms,” which are the “atoms” meant by Democritos (as applied by Dalton), in their unstable form, which was anticipated by Epicuros, for imaging of tissues or diseases and for therapy of malignant or benign diseases.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Sfakianakis GN, Mallin W (1999) Scintigraphic neuroimaging in paediatrics. In: Panteliadis CP, Darris BT (eds) Encyclopedia of pediatric neurology theory and practice, Thessaloniki, Greece. 2nd edn:pp 164–195
Hustinx R, Alavi A (1999) SPECT and PET imaging of brain tumors. Neuroimaging Clin N Am 9(4):751–766
Alavi JB et al (1988) Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62(6):1074–1078
Del Sole A et al (2001) Anatomical and biochemical investigation of primary brain tumours. Eur J Nucl Med 28(12):1851–1872
Levivier M et al (1995) Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J Neurosurg 82(3):445–452
Tyler JL et al (1987) Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 28(7):1123–1133
Kaschten B et al (1998) Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39(5):778–785
Delbeke D et al (1995) Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195(1):47–52
Di Chiro G et al (1987) Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 164(2):521–526
Padma MV et al (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64(3):227–237
De Witte O et al (1996) Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 39(3):470–476, discussion 476–477
Olivero WC, Dulebohn SC, Lister JR (1995) The use of PET in evaluating patients with primary brain tumours: is it useful? J Neurol Neurosurg Psychiatry 58(2):250–252
Ricci PE et al (1998) Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 19(3):407–413
Krohn KA et al (2005) True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 32(7):663–671
Wong TZ et al (2004) PET and brain tumor image fusion. Cancer J 10(4):234–242
Chen W (2007) Clinical applications of PET in brain tumors. J Nucl Med 48(9):1468–1481
Spence AM et al (2004) 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 45(10):1653–1659
Kubota K et al (1984) Tumor detection with carbon-11-labelled amino acids. Eur J Nucl Med 9(3):136–140
Fulham MJ et al (1993) Neuroimaging of juvenile pilocytic astrocytomas: an enigma. Radiology 189(1):221–225
Ogawa T et al (1993) Cerebral glioma: evaluation with methionine PET. Radiology 186(1):45–53
Ogawa T et al (1991) Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 32(3):197–202
Ogawa T et al (1994) Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. Radiographics 14(1):101–110
Herholz K et al (1998) 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50(5):1316–1322
Derlon JM et al (1997) The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery 40(2):276–287, discussion 287–288
Goldman S et al (1997) Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38(9):1459–1462
Pirotte B et al (2004) Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 101(3):476–483
De Witte O et al (1994) Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 74(10):2836–2842
Chen W et al (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47(6):904–911
Seibyl JP, Chen W, Silverman DH (2007) 3, 4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Semin Nucl Med 37(6):440–450
Popperl G et al (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34(12):1933–1942
Vander Borght T et al (1991) Noninvasive measurement of liver regeneration with positron emission tomography and [2-11C]thymidine. Gastroenterology 101(3):794–799
Vander Borght T et al (1994) Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 35(6):974–982
Goethals P et al (1996) [Methyl-carbon-11] thymidine for in vivo measurement of cell proliferation. J Nucl Med 37(6):1048–1052
Mankoff DA et al (1998) Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med 39(6):1043–1055
De Reuck J et al (1999) [Methyl-11C]thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. Acta Neurol Belg 99(2):118–125
Pruim J et al (1995) Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 197(1):221–226
Willemsen AT et al (1995) In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-11C]-tyrosine and PET. J Nucl Med 36(3):411–419
de Wolde H et al (1997) Proliferative activity in human brain tumors: comparison of histopathology and L-[1-(11)C]tyrosine PET. J Nucl Med 38(9):1369–1374
Hara T et al (1997) PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 38(6):842–847
Hustinx R et al (2003) Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. J Nucl Med 44(4):533–539
Rutten I et al (2007) PET/CT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: initial report. J Nucl Med 48(5):720–725
Lucignani G et al (1997) Differentiation of clinically non-functioning pituitary adenomas from meningiomas and craniopharyngiomas by positron emission tomography with [18F]fluoro-ethyl-spiperone. Eur J Nucl Med 24(9):1149–1155
Black KL et al (1989) Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 71(3):342–346
Dierckx RA et al (1994) Sensitivity and specificity of thallium-201 single-photon emission tomography in the functional detection and differential diagnosis of brain tumours. Eur J Nucl Med 21(7):621–633
Kaplan WD et al (1987) Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med 28(1):47–52
Rollins NK, Lowry PA, Shapiro KN (1995) Comparison of gadolinium-enhanced MR and thallium-201 single photon emission computed tomography in pediatric brain tumors. Pediatr Neurosurg 22(1):8–14
Maria BL et al (1997) Correlation between gadolinium-diethylenetriaminepentaacetic acid contrast enhancement and thallium-201 chloride uptake in pediatric brainstem glioma. J Child Neurol 12(6):341–348
Ricci M et al (1996) Relationship between thallium-201 uptake by supratentorial glioblastomas and their morphological characteristics on magnetic resonance imaging. Eur J Nucl Med 23(5):524–529
Ishibashi M et al (1995) Thallium-201 in brain tumors: relationship between tumor cell activity in astrocytic tumor and proliferating cell nuclear antigen. J Nucl Med 36(12):2201–2206
Oriuchi N et al (1993) Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: relationship to histologic grade, prognosis and proliferative activities. J Nucl Med 34(12):2085–2089
Oriuchi N et al (1996) Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med 37(3):457–462
Hirano T et al (1997) Technetium-99m(V)-DMSA and thallium-201 in brain tumor imaging: correlation with histology and malignant grade. J Nucl Med 38(11):1741–1749
Zingale A et al (1995) Thallium-201-SPECT and 99Tc-HM-PAO SPECT imaging to study functionally cerebral supratentorial neoplasms: the biological basis of the functional imaging interpretation. J Neurosurg Sci 39(4):227–235
Buchpiguel CA et al (1995) PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. J Nucl Med 36(1):159–164
Bagni B et al (1995) SPET imaging of intracranial tumours with 99Tcm-sestamibi. Nucl Med Commun 16(4):258–264
Beauchesne P et al (1998) Is cerebral tomoscintigraphy with 99mTc-MIBI useful in the diagnosis of local recurrence in patients with malignant gliomas? Cancer Radiother 2(1):42–48
Maffioli L et al (1996) Clinical role of technetium-99m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumours. Eur J Nucl Med 23(3):308–311
O’Tuama LA et al (1993) Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. J Nucl Med 34(7):1045–1051
Shih WJ et al (1993) Tc-99m sestamibi uptake by cerebellar metastasis from bronchogenic carcinoma. Clin Nucl Med 18(10):887–890
Kuwert T et al (1996) Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 23(10):1345–1353
Kuwert T et al (1997) Iodine-123-alpha-methyl tyrosine in gliomas: correlation with cellular density and proliferative activity. J Nucl Med 38(10):1551–1555
Langen KJ et al (2000) Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl-L-methionine. J Nucl Med 41(7):1250–1255
Woesler B et al (1997) Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose. Eur J Nucl Med 24(4):428–434
Hellwig D et al (2008) Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-alpha-methyl-tyrosine for SPECT imaging of gliomas. Eur J Nucl Med Mol Imaging 35(1):24–31
Pacak K et al (2004) The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing’s syndrome. J Clin Endocrinol Metab 89(5):2214–2221
Tabarin A et al (1999) Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 84(4):1193–1202
Acosta-Gomez MJ et al (2005) The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. Br J Radiol 78(926):110–115
Moulik PK et al (2002) The role of somatostatin receptor scintigraphy in the management of pituitary tumours. Nucl Med Commun 23(2):117–120
de Herder WW et al (2007) Diagnostic imaging of dopamine receptors in pituitary adenomas. Eur J Endocrinol 156(1):53–56
Kessler LS et al (1998) Thallium-201 brain SPECT of lymphoma in AIDS patients: pitfalls and technique optimization. AJNR Am J Neuroradiol 19(6):1105–1109
Lorberboym M et al (1998) Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 39(8):1366–1369
O’Doherty MJ et al (1997) PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 38(10):1575–1583
Villringer K et al (1995) Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr 19(4):532–536
Krishna L et al (1992) Abnormal intracerebral thallium localization in a bacterial brain abscess. J Nucl Med 33(11):2017–2019
Tonami N et al (1990) Thallium-201 accumulation in cerebral candidiasis: unexpected finding on SPECT. Clin Nucl Med 15(6):397–400
Gorniak RJ et al (1997) Thallium-201 uptake in cytomegalovirus encephalitis. J Nucl Med 38(9):1386–1388
Bernat I, Toth G, Kovacs L (1994) Tumour-like thallium-201 accumulation in brain infarcts, an unexpected finding on single-photon emission tomography. Eur J Nucl Med 21(3):191–195
Kallen K et al (1997) Evaluation of malignancy in ring enhancing brain lesions on CT by thallium-201 SPECT. J Neurol Neurosurg Psychiatry 63(5):569–574
Douglas JG et al (2006) [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 64(3):886–891
Grosu AL et al (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63(2):511–519
Cher LM et al (2006) Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 47(3):410–418
Bruehlmeier M et al (2004) Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 45(11):1851–1859
Rozental JM, Levine RL, Nickles RJ (1991) Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance. J Neurooncol 10(1):75–83
Rozental JM et al (1993) Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neurooncol 15(1):57–66
Barker FG II et al (1997) 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79(1):115–126
Raez L et al (1999) Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses 15(8):713–719
Shields AF et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4(11):1334–1336
Rasey JS et al (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43(9):1210–1217
Saga T et al (2006) Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med 31(12):774–780
Yamamoto Y et al (2006) 3′-Deoxy-3′-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol 8(6):340–347
Chen W et al (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25(30):4714–4721
Pauleit D et al (2005) O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128(pt 3):678–687
Roelcke U et al (1998) Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 39(5):879–884
Rachinger W et al (2005) Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57(3):505–511
Schwartz RB et al (1991) Radiation necrosis vs high-grade recurrent glioma: differentiation by using dual-isotope SPECT with 201TI and 99mTc-HMPAO. AJNR Am J Neuroradiol 12(6):1187–1192
Schwartz RB et al (1998) Dual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiforme: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapy. J Neurosurg 89(1):60–68
Lorberboym M et al (1997) The role of thallium-201 uptake and retention in intracranial tumors after radiotherapy. J Nucl Med 38(2):223–226
Vertosick FT Jr et al (1994) Correlation of thallium-201 single photon emission computed tomography and survival after treatment failure in patients with glioblastoma multiforme. Neurosurgery 34(3):396–401
Haldemann AR et al (1995) Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J Nucl Med 36(3):403–410
Schmidt M et al (1998) Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 25(7):675–686
Klutmann S et al (1998) Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med 39(11):1913–1917
Nelson SJ, Vigneron DB, Dillon WP (1999) Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 12(3):123–138
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Sfakianakis, G.N., Sfakianaki, E., Gomes, H. (2011). Scintigraphy for Brain Tumors. In: Drevelegas, A. (eds) Imaging of Brain Tumors with Histological Correlations. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-87650-2_14
Download citation
DOI: https://doi.org/10.1007/978-3-540-87650-2_14
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-87648-9
Online ISBN: 978-3-540-87650-2
eBook Packages: MedicineMedicine (R0)